HomeAbout

TL;DR CNBC


Novo Nordisk's diabetes pill slashes risk of cardiovascular complications by 14% after four years - TL;DR CNBC

Novo Nordisk's diabetes pill slashes risk of cardiovascular complications by 14% after four years

Publishing timestamp: 2025-03-29 15:02:07


Summary

Novo Nordisk's diabetes pill Rybelsus showed cardiovascular benefits in a late-stage trial, lowering the risk of cardiovascular-related death, heart attack, and stroke by 14% compared to a placebo. This paves the way for Rybelsus to become a new treatment option for people with diabetes and established heart disease.


Sentiment: POSITIVE

Tickers: LLYNOVO.B-DKNVO

Keywords: pharmaceuticalslilly drnbusiness newsbiotechnologynovo nordisk a/shealth care industrybiotech and pharmaceuticalssciencebusinessbreaking news: business

Source: https://www.cnbc.com/2025/03/29/novo-nordisks-diabetes-pill-rybelsus-slashes-cardiovascular-risk.html


Developed by Leo Phan